In its annual listing, the magazine names ten companies that are at the forefront of providing drug discovery and development solutions and impacting the industry. The panel chose Systasy, stating that all top 10 companies “demonstrate an ability to develop innovative technologies combined with outstanding customer service.”
March 26, 2019 – MunichThe German Ministry of Education and Research (BMBF) has assigned the VIP+ validation award 2019 to the EXTassay project. The EXTassay technology allows to directly examine what´s going wrong in neuronal cells of patients suffering from complex brain diseases.
Schizophrenia is a complex human disease, caused both by individual genetic variation and lifestyle. Genome-wide association studies have implicated many molecular targets and biological pathways with this disease. One these pathways associated with schizophrenia is the so-called Neuregulin1 (Nrg1)-ERBB4 signaling pathway.
Systasy Bioscience GmbH and Boehringer Ingelheim International GmbH(BI) entered a non-exclusive license agreement for cell-based splitSENSOR assays providing BI with the options to screen for selected target activities relevant to schizophrenia.
Systasy Bioscience GmbH and Sygnis AG closed a patent transfer deal today. A patent transfer agreement for Double Switch technology was signed.